Dr Reddy's Labs lines up Rs 1,500 cr capex with focus on biosimilars, injectables https://ift.tt/Vumtv9B

Elaborating on the overall strategies, Dr Reddy's Laboratories CEO Erez Israeli said the company's R&D is focusing on creating "as much as possible on differentiated products, on biosimilars, on products that have bigger potential." The products, especially injectables, which the company has developed for the US are also being introduced in other markets, he added.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/9xb4fip